Pharmaceuticals
First Patient Dosed in Phase II Renal Cancer Theranostics Study
MELBOURNE, Australia and INDIANAPOLIS, May 5, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in the 'STARLITE 2' Phase II study of the Company's investigational renal cancer therapy, TLX250 (177 Lu-DOTA-girentu...
2022-05-05 05:00
3404
Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets*
LUGANO, Switzerland, and SINGAPORE, May 4, 2022 /PRNewswire/ -- Juniper Biologics Pte Ltd, a science-led healthcare company focused on researching, developing and commercializing novel therapies, and Helsinn Group, a fully integrated, global biopharma company with a diversified pipeline of innova...
2022-05-04 14:00
2924
China Mobile Hong Kong Launches Online Medical App "Dr. HK"
Four Major Features Providing Doctor Consultation and Prescription While Staying at Home Medicine Doorstep Delivery in 4 hours at the earliest Free of Charge Video Consultation, Medication and Delivery for First 500 Users HONG KONG, May 4, 2022 /PRNewswire/ -- With the rise of the digital lifest...
2022-05-04 12:00
6389
Servatus strengthens Board with appointment of biopharmaceutical division head at Boehringer Ingelheim, Dr Uwe Buecheler
* New Board appointment deepens and consolidates Servatus' extensive commercial and scientific expertise for its global biotherapeutics programs * Dr Buecheler joins as Non-Executive Director from leading pharmaceutical giant Boehringer Ingelheim inGermany, where he is both Senior Vice Preside...
2022-05-02 07:36
4687
Asia Pacific Initiative on Reproduction (ASPIRE) 2022 Congress: Linking male infertility diagnosis with the window to future health trajectories
SINGAPORE, May 1, 2022 /PRNewswire/ -- Male infertility factors are emerging as likely biomarkers for later life health events including hospital treatments and possible premature death from conditions such as cancer, cardiovascular and metabolic diseases. Lifestyle and social factors, includi...
2022-05-01 13:30
5563
Hikma confirms that it has not signed a licensing agreement with Opiant Pharmaceuticals
LONDON, April 30, 2022 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma) confirms that it has not entered into any transaction with Opiant Pharmaceuticals, contrary to a PR Newswire announcement issued today indicating that Opiant Pharmaceuticals and Hikma have entered into a commercialisation an...
2022-04-30 02:08
3161
Transcenta to Present Clinical Trial Data of TST001 and MSB0254 at 2022 ASCO Annual Meeting
SUZHOU, China, April 29, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that the abstracts o...
2022-04-29 10:33
4414
Transcenta Announces First Patient Dosed in China Study of Anti-sclerostin Monoclonal Antibody TST002 for the Treatment of Osteoporosis
SUZHOU, China, April 28, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces the successful dosin...
2022-04-28 17:06
3356
CStone to present the latest clinical results of anti-PD-L1 antibody sugemalimab and anti-PD-1 antibody nofazinlimab at ASCO 2022
* Results from GEMSTONE-201 study of sugemalimab, the first successful registrational clinical study to date evaluating an anti-PD-(L)1 antibody targeting patients with relapsed or refractory extranodal natural killer/T-cell lymphoma, will be presented in an oral abstract session * The protoc...
2022-04-28 08:00
4061
FDA Approves Direct Biologics to Proceed with a Landmark Phase 3 Acute Respiratory Distress Syndrome (ARDS) Trial
AUSTIN, Texas, April 27, 2022 /PRNewswire/ -- Direct Biologics, a regenerative biotechnology company with a groundbreaking extracellular vesicle (EV) platform technology, announced today that the FDA has approved the company to proceed with its Phase 3 clinical trial using its investigational EV ...
2022-04-27 00:09
4058
Seegene unveils world's first commercialized '3 Ct' PCR assay
* Provides Ct value of three targets in one channel; '3 Ct' PCR assay to launch in H1 * "Dream MDx technology" developed based on Seegene's 20-year expertise; combines 19 different patented technologies, including DPO™, TOCE™, MuDT™ * '3 Ct' to lay foundation for automated syndromic testing ...
2022-04-26 20:32
2696
Holmusk Announces Publication of Seminal Paper on Real-World Evidence (RWE) Platform NeuroBlu
NEW YORK, April 26, 2022 /PRNewswire/ -- Holmusk, a leading global data science and health technology company building the world's largest real-world evidence (RWE) platform for behavioral health, is pleased to share with the scientific community in-depth details about its platform via thepublica...
2022-04-26 19:30
2747
Octapharma to address unmet needs in von Willebrand disease as a proud sponsor of WFH 2022 World Congress
LACHEN, Switzerland, April 26, 2022 /PRNewswire/ -- As part of its ongoing commitment to the global bleeding disorders community, Octapharma is pleased to be a Gold Sponsor of the upcoming World Federation of Haemophilia (WFH) 2022 World Congress, taking place fromMay 8 to 11, 2022. This continue...
2022-04-26 16:00
2989
Adge Pharmaceuticals partners with Cyan Bio of Korea to advance treatments for rare pediatric diseases in Asian countries
MOUNTAIN VIEW, Calif., April 26, 2022 /PRNewswire/ -- Adge Pharmaceuticals ("Adge") has entered into a license agreement with Korea-based Cyan Bio, Inc. ("Cyan"). Cyan will receive exclusive rights for commercialization of elocalcitol in key territories inAsia for the treatment of the Rett Syndro...
2022-04-26 07:00
2196
JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 200 Chinese Patients
SHANGHAI, April 25, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, disclosed that as ofApril 12, 2022, its cell immunotherapy drugs have been successfully ...
2022-04-25 15:08
5035
CStone Announces Results From Phase 3 AGILE Data of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia Published in the New England Journal of Medicine
* Results from the trial present a significant advancement for patients dealing with previously untreated IDH1-mutated AML * Global Phase 3 trial of TIBSOVO (ivosidenib tablets) met its primary endpoint of event-free survival and all key secondary endpoints, complete remission rate, overall s...
2022-04-22 08:02
4705
Lynk Pharmaceuticals Announces Clinical Approval in China for Its Class I New Drug LNK01004
HANGZHOU, China, April 22, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that its Class I innovative drug LNK01004, has been approved by National Medical Products Administration (NMPA) for c...
2022-04-22 08:00
4255
Telix Further Strengthens European Distribution Network for Illuccix
MELBOURNE, Australia and LIÈGE, Belgium, April 22, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces agreements with Sociedade Avanço, Unipessoal, LDA (Avanço) and THP Medical Products Vertriebs GmbH (THP) for the distribution of Telix's prostate ca...
2022-04-22 07:10
4393
Terran Biosciences announces licensing deal with Sanofi for two late-stage CNS pipeline assets
* Terran to advance the development of two of Sanofi's Phase 3 CNS therapeutics * Transaction includes worldwide exclusive rights for development and commercialization in all fields of use NEW YORK, April 21, 2022 /PRNewswire/ -- Terran Biosciences, Inc. ("Terran"), a biotech platform company...
2022-04-21 22:39
5116
Transcenta Successfully Passed the Audit of EU Qualified Person for the Manufacturing of TST001
SUZHOU, China, April 21, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that HJB (Hangzhou) ...
2022-04-21 19:20
4058
Week's Top Stories
Most Reposted
DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 277 media titles]
2026-10-06 05:28SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 276 media titles]
2026-10-07 11:50Zenika CTO Adrien Nortain Moves Base to Singapore to Strengthen Technical Leadership in Asia
[Picked up by 271 media titles]
2026-10-01 10:00
Vestas Powers Up Vietnam's Clean Energy Ambitions with Two New Projects Under PDP8 Totaling 16 Wind Turbines
[Picked up by 263 media titles]
2026-10-02 16:27
Southeast Asia's China travel map is widening, Traveloka platform data shows
[Picked up by 262 media titles]
2026-10-05 11:51Most Read
MixVio AI Launches Unified Creative Workspace Across 26 AI Generation Routes
2026-10-02 00:30
23969